Pilman An Editorial Journal by Tapan Ray | Pharmaceuticals & Healthcare

Tagraging

Balancing IPR with Public Health Interest: Brickbats, Power Play and Bouquets

B

It is now a widely accepted dictum that Intellectual Property Rights (IPR), especially pharma patents, help fostering innovation and is critical in meeting unmet needs of the patients. However, the moot question still remains, what type pharmaceutical invention, should deserve market exclusivity or monopoly with overall freedom in pricing, keeping larger public health interest in mind. In line with this thinking, for quite sometime a raging global debate has brought to the fore that there are...

Indian Patent office (IPO) asks for details of ‘working of patents’ in India – does it herald the beginning of a new chapter in the IPR regime of the country or it could trigger another raging debate

I

A Public Notice dated 24/12/2009 issued by the Controller General of Patents, Design & Trade Marks, directing all Patentees and Licensees to furnish information in Form No.27 on ‘Working of Patents’ as prescribed under Section 146 of the Patents Act (as amended) read with Rule 131 of the Patents Rule 2003 ( as amended). The notice also draws attention to penalty provisions in the Patent Act, in case of non-submission of the aforesaid information.The Last date for filing the...

Biosimilar Drugs -A raging scientific debate with mounting global commercial interest

B

On December 11, 2008, Reuters reported that two days after Merck & Co. announced a major push into generic versions of biotechnology medicines, Eli Lilly & Co. signaled similar aspirations. This report raised many eyebrows in the global pharmaceutical industry, in the midst of a raging scientific debate on this issue. Be that as it may, many felt that this announcement ushered in the beginning of a new era. An era of intense future competition with Biosimilar drugs in the world market...

Pilman An Editorial Journal by Tapan Ray | Pharmaceuticals & Healthcare

Tapan Ray

Tapan Ray

Tapan Ray is a veteran pharmaceutical executive, healthcare strategist, and influential thought leader with decades of leadership experience in the healthcare industry. Through this blog, he explores the forces transforming medicine from pharmaceutical innovation and digital transformation to healthcare policy and patient-centric business models.

Combining extensive industry experience with sharp analytical insight, Tapan challenges conventional thinking and offers fresh perspectives on how bold ideas can drive meaningful change in healthcare and improve lives.

Follow Me